Plunging valuations have made biotech companies tempting acquisition targets for cash-rich Big Pharma and a flurry of deals is just what the battered sector needs to turn a corner.

For many in the biotech space, the pandemic was a chance to prove their worth, creating vaccines in record time and, for some, earning significant profits. Now, with the pandemic receding amidst rumblings of a global recession, the industry is facing what some consider the worst times since its inception.

Ginkgo Bioworks is acquiring Zymergen for around $300 million to utilize its data science and machine learning capabilities for a wide range of biological engineering approaches. 

The full-service agency Emcay is uniquely designed to provide a perfect balance of pharmaceutical knowledge and multicultural insight. Fingerpaint Marketing also announced the creation of Fingerpaint Multicultural, a specialty offering that will focus solely on Pharmacultural® marketing.

Guidemark Health and Cyan Health have today rebranded, changing their names to Lumanity. The two agencies were acquired by Lumanity in 2021.

“We expect that this acquisition and Ipsen’s commitment to invest in the oncology space will ensure our epigenetic pipeline continues to advance in a way we could not have done on our own to bring transformative cancer therapies to patients in need,” Bogle said in a statement,” company CEO David Loew said in a statement.

Lumanity today announced the acquisition of Endpoint Outcomes, a company specializing in harnessing the voice of patients to document the impact of treatments on health-related quality of life. Lumanity CEO Jon Williams says, “We look forward to working with our new colleagues to define and build market-leading, patient-centered research services to address both HTA and payer needs, and we are confident that our work will yield innovative new solutions for our clients and partners.”

EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, today unveiled EVERSANA INTOUCH, marking the transformation of its full-service, global healthcare agency network serving the life sciences industry. Combining the power of world-class creative, media and digital innovation with payer, patient, and healthcare communications expertise, EVERSANA INTOUCH reinvents life sciences marketing as the first and only agency accelerating brand performance through insights and seamless connectivity to EVERSANA’s integrated commercialization solutions.

Fishawack Health (FH) announces the acquisition of leading healthcare consulting and advisory firm Avalere Health from Inovalon, which acquired the consultancy in 2015.

Bristol Myers Squibb Co. said on Friday it will acquire drug developer Turning Point Therapeutics Inc. for $4.1 billion in cash to help bolster its arsenal of cancer drugs.